Immune diseases like type 1 diabetes and multiple sclerosis can lead to severe complications in patients, yet there are currently very limited treatment options which mitigate their impact at best and no opportunity for a cure. However, the discovery of a new technology platform at Belgium’s KU Leuven Hospital offers new hope for these patients.
Imotopes™ are modified HLA class II epitopes which block the immune processes that cause immune-mediated diseases, providing a potentially curative approach to severe chronic diseases. Imotopes™ induce cytolytic T cells that specifically eliminate antigen-presenting cells without affecting other functions of the immune system, intervening and stopping an autoimmune response at a time when attacked tissues can still regenerate.
Imotopes™ is the product of Imcyse, a clinical-stage biopharmaceutical company based in Lieges, Belgium, pioneering the development of this new class of active, specific immunotherapies. This technology is most advanced in the area of Type 1 Diabetes, with the development of IMCY-0098.
IMCY-0098 is a novel insulin-based Imotope™. In August 2019, Imcyse presented promising results from its first in human trial, a phase Ib safety study with IMCY-0098 in patients with early type 1 diabetes (T1D): IMCY-0098 is safe, well-tolerated, does not accelerate disease and is associated with immune modulation.
Imcyse is working with top clinicians at KU Leuven, as well as being part of INNODIA, a global partnership to fight Type 1 Diabetes. Through INNODIA’s Patient Advisory Committee Imcyse will ensure they deliver the treatment that Type 1 Diabetes patients want and need.
As clinical trials progress and basic research continues, the Imotope™ technology platform has the potential to address a wide range of indications in the vast field of immunology from diabetes to even less treatable conditions – with the potential to create a paradigm shift in the way these conditions are treated. Video Rating: / 5
The video shows the timelapse of the coronavirus (COVID-19) by map worldwide from January 2020 to December 2021. The virus originated from Wuhan, Hubei, China in late 2019 and spread to all countries except for Turkmenistan and North Korea outside of Oceania.
A growing number of countries now require people arriving from China to show negative COVID-19 tests. Beijing has re-opened its borders after nearly three years of pandemic travel restrictions – but China’s surging coronavirus infections are making other nations nervous.
Subscribe: https://www.youtube.com/user/deutschewelleenglish?sub_confirmation=1
For more news go to: http://www.dw.com/en/
Follow DW on social media:
►Facebook: https://www.facebook.com/deutschewellenews/
►Twitter: https://twitter.com/dwnews
►Instagram: https://www.instagram.com/dwnews
►Twitch: https://www.twitch.tv/dwnews_hangout
Für Videos in deutscher Sprache besuchen Sie: https://www.youtube.com/dwdeutsch
This patient came in to see Dr. Freels to trim the calluses and blood blisters that were forming on the tips of her toes and ended up discovering some surprise, gunky fluid at the end of the procedure!
This patient is diabetic, so having her feet tended to by a professional is CRUCIAL in order to prevent serious healing problems.
Dr. Freels ended up trimming EIGHT rock-hard calluses and TWO oozing blood blisters!
Dr. Sunil Dargar, MBBS, MD, Pathologist, New Delhi, will talk about whether the urine sugar test is reliable. In earlier days, only urine sugar test was available to detect diabetes.
The urine test may not be frequently prescribed test nowadays, but its importance still remains. Presence of acetone, ketone, microalbumin or 24-hour albumin in urine is very relevant in diabetic patients.
Dr. Dargar will explain why it is necessary to know the sugar, acetone or ketone present in diabetic patient’s urine. The enzymes which are available to detect the glucose in urine are for ketones which are very reliable and can detect even a small amount of ketones and sugar in urine. Also, the urine sugar test can help to detect intermittent proteinuria in diabetic patients.
